CAS: 494-19-9; 10,11-Dihydro-5H-Dibenzo[b,F]Azepine

上下游产品

CAS号6796-01-6 o-nitrobibenzyl | CAS号256-96-2 亚氨基芪 | CAS号33948-19-5 10,11-二氢-5H-二苯并... | CAS号13080-75-6 1-(10,11-二氢-5H-... | CAS号152700-41-9 3-(3,5-dichloro... | CAS号113-52-0 丙咪嗪盐酸盐 | CAS号58-28-6 去甲丙咪嗪盐酸盐 | CAS号23868-11-3 Benzoic acid, 2... | CAS号53044-24-9 2-(Phenylamino)... | CAS号3564-73-6 双氢卡马西平 | CAS号33948-22-0 亚氨基芪甲酰氯 | CAS号33948-19-5 10,11-二氢-5H-二苯并... | CAS号50-49-7 米帕明 | CAS号19054-67-2 3-CHLORO-1-(10,... | CAS号21186-33-4 5,6-dihydrobenz... | CAS号256-96-2 亚氨基芪 | CAS号95-53-4 邻甲苯胺 | CAS号260-94-6 吖啶 | CAS号611-64-3 9-甲基吖啶

丙咪嗪置于peroxidase From Horseradish Type Vi,双氧水体系中,化学反应 1.0H,反应生成 亚氨基二苄
参考文献:In Vitro Studies Of Dna Damage Caused By Tricyclic Antidepressants: A Role Of Peroxidase In The Side Effects Of The Drugs
标题:In Vitro Studies Of Dna Damage Caused By Tricyclic Antidepressants: A Role Of Peroxidase In The Side Effects Of The Drugs
摘要:Studies Show That Tricyclic Antidepressants Prescribed For Migraines,Anxiety,And Child Enuresis Have Numerous Adverse Effects In Living Cells. One Of The Undesired Outcomes Observed Under Treatment With These Drugs Is Dna Damage. However,The Mechanisms Underlying Damage Have Yet To Be Elucidated. We Performed In Vitro Studies Of The Dna Damage Caused By Four Tricyclic Antidepressants: Imipramine,Amitriptyline,Opipramol,And Protriptyline. We Focused Particularly On The Dna Damage Aided By Peroxidases. As A Model Of A Peroxidase,We Used Horseradish Peroxidase (Hrp). At Ph 7,Reactions Of Hrp With Excess Hydrogen Peroxide And Imipramine Yielded An Intense Purple Color And A Broad Absorption Spectrum With The Maximum Intensity At 522 Nm. Reactions Performed Between Dna And Imipramine In The Presence Of H2O2 And Hrp Resulted In The Disappearance Of The Dna Band. In The Case Of The Other Three Drugs,This Effect Was Not Observed. Extraction Of The Dna From The Reaction Mixture Indicated That Dna Is Degraded In The Reaction Between Imipramine And H2O2 Catalyzed By Hrp. The Final Product Of Imipramine Oxidation Was Identified As Iminodibenzyl. We Hypothesize That The Damage To Dna Was Caused By An Imipramine Reactive Intermediate.
DOI:10.1021/tx100221B

专利信息

专利号:US-10414903-B2
优先权日:2016-11-11
标题 :Methods for synthesis of end-functionalized polyolefins
发明人：GUIRONNET DAMIEN S; HYATT MICHAEL G; WALSH DYLAN J
权利人:UNIV ILLINOIS
摘要:A strategy for the synthesis of semi-telechelic polyethylene through the palladium diimine-catalyzed chain transfer polymerization of ethylene using various silanes as chain transfer agents is reported. Polymer molecular weight and end-group chemical structure can be tuned by varying the chain transfer agent as well as its concentration. NMR spectroscopy confirms that the silicon of the chain transfer agent is incorporated into the polymer. The stability of the catalyst toward polar monomer enables the chain transfer polymerization of semi-telechelic poly(ethylene-methyl acrylate) copolymers.

专利号:US-6225329-B1
优先权日:1998-03-12
标 题 :Modulators of protein tyrosine phosphatases (PTPases)
发明人：RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOELLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
权利人:NOVO NORDISK AS
摘要:The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, n wherein A, R 1 , R 2 , R 3 , R 4 , R 16 and R 17 are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:US-2005119332-A1
优先权日:1998-03-12
标 题 :Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
发明人：JEPPESEN LONE; ANDERSEN HENRIK S; OLSEN OLE H; JUDGE LUKE M; HOLSWORTH DANIEL D; BAKIR FARID; AXE FRANK U; GE YU
摘要:The present invention provides novel compounds of formula 1a, n nnovel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:US-9388147-B2
优先权日:2009-11-13
标题 :Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
发明人：MARTINBOROUGH ESTHER; BOEHM MARCUS F; YEAGER ADAM RICHARD; TAMIYA JUNKO; HUANG LIMING; BRAHMACHARY ENUGURTHI; MOORJANI MANISHA; TIMONY GREGG ALAN; BROOKS JENNIFER L; PEACH ROBERT; SCOTT FIONA LORRAINE; HANSON MICHAEL ALLEN
权利人:RECEPTOS INC; CELGENE INTERNAT II SÃ?RL
摘要:Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

专利号:WO-9946244-A1
优先权日:1998-03-12
标题 :Modulators of protein tyrosine phosphatases (ptpases)
发明人：JEPPESEN LONE; ANDERSEN HENRIK SUNE; OLSEN OLE HVILSTED; JUDGE LUKE MILBURN; HOLSWORTH DANIEL DALE; BAKIR FARID; AXE FRANK URBAN; GE YU
权利人:NOVO NORDISK AS; ONTOGEN CORP
摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:WO-9946267-A1
优先权日:1998-03-12
标题 :Modulators of protein tyrosine phosphatases (ptpases)
发明人：MOELLER NIELS PETER HUNDAHL; ANDERSEN HENRIK SUNE; IVERSEN LARS FOGH; OLSEN OLE HVILSTED; BRANNER SVEN; HOLSWORTH DANIEL DALE; BAKIR FARID; JUDGE LUKE MILBURN; AXE FRANK URBAN; JONES TODD KEVIN; RIPKA WILIAM CHARLES; GE YU; UYEDA ROY TERUYUKI
权利人:NOVO NORDISK AS; ONTOGEN CORP
摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.